- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03242317
A Prospective Study to Evaluate the Raindrop Near Vision Inlay With Mitomycin C
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Treated With Mitomycin C During Surgery and Extended Steroid After Surgery
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
New York
-
Amherst, New York, Estados Unidos, 14228
- Recrutamento
- Fichte Endl & Elmer Eyecare
-
Contato:
- Micheal J Endl, MD
- Número de telefone: 716-564-2020
- E-mail: mpderme@aol.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Patients require a near reading add from +1.5 to +2.5 D in the non-dominant eye.
Patients have a photopic pupil size of at least 3.0 mm in the non-dominant eye. Patients have a corneal thickness greater than or equal to 500 microns in the non-dominant eye.
Patients have corrected distance and near visual acuity of 20/25 or better in each eye.
Patients have distance corrected near visual acuity of 20/40 or worse in each eye.
Patients are willing and able to sign and understand a written Informed Consent Form prior to any study-specific procedures.
Patients are willing and able to return for scheduled follow-up examinations for 24 months after the corneal inlay surgery.
Exclusion Criteria:
Patients with prior ocular surgery. Patients with clinically significant dry eye (i.e., significant diffuse punctate staining with fluorescein and a tear breakup time less than 8 s) in either eye.
Patients with a planned corneal residual bed thickness that is less than 300 microns (corneal thickness - (intended ablation depth + intended flap thickness)).
Patients with macular pathology based on dilated fundus exam and/or optical coherence tomography (OCT) image.
Patients who would be co-managed by an ophthalmologist or optometrist who is not approved as a ReVision Optics investigator.
Patients with ocular pathology or disease (including pupil pathology such as fixated pupils) that might confound the outcome or increase the risk of adverse event.
Patients taking systemic or topical medications that might confound the outcome or increase the risk of adverse event. Patients taking isotretinoin or amiodarone hydrochloride and any other medication that affects the tear film or accommodation, including but not limited to, mydriatic, cycloplegic and mitotic agents, tricyclic, phenothiazines, benzodiazepines, and first generation antihistamines.
Patients with known sensitivity to any planned study medications. Patients with residual, recurrent, active or uncontrolled eyelid disease. Patients with significant corneal asymmetry or irregular topography. Patients with clinically significant anterior segment pathology. Patients with any corneal abnormality, including but not limited to, slit lamp findings for corneal staining Grade 3 or higher, recurrent corneal erosion or severe basement membrane disease, and pterygium extending onto the cornea.
Patients with ophthalmoscopic/topographic signs of keratoconus or those who are keratoconus suspect.
Patients with history of Herpes zoster or Herpes simplex keratitis. Patients with any progressive retinal disease or subjects with a history or evidence of retinal vascular occlusion and/or hypercoagulability, because of the risks associated with high pressures during suction application.
Patients with known history of steroid-responsive intraocular pressure increases, glaucoma, preoperative IOP > 21 mm Hg, or are otherwise suspected of having glaucoma.
Patients with amblyopia or strabismus or those who are at risk for developing strabismus postoperatively as determined by corneal light reflex and cover-uncover testing.
Patients with diabetic retinopathy, collagen, vascular, diagnosed autoimmune disease (e.g., lupus, rheumatoid arthritis, fibromylagia), immunodeficiency (e.g., HIV), connective tissue disease, or clinically significant atopic syndrome such as allergies or asthma.
Patients on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing.
Patients with any type of active cancer (ophthalmic or non-ophthalmic). Patients with uncontrolled infections of any kind. Patients who are pregnant, lactating, of child-bearing potential and not practicing a medically approved method of birth control, or planning to become pregnant during the course of the trial, and patients with other conditions associated with fluctuation of hormones that could lead to refractive changes.
Patients who actively participate in contact sports (i.e., boxing, martial arts) where impacts to the face and eye are a normal occurrence.
Patients participating in any other ophthalmic or non-ophthalmic drug/device clinical trials during the time of this clinical investigation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Mitomycin C + Raindrop Near Vision Inlay
The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
|
The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay.
This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Acuidade visual não corrigida
Prazo: 24 meses
|
Após o procedimento de inlay, os pacientes obterão acuidade visual funcional para perto no olho inlay e acuidade funcional para longe binocularmente.
|
24 meses
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Incidência de Reação da Córnea
Prazo: 24 meses
|
Pacientes tratados com MMC de baixa dose e curta duração no intraoperatório e, em seguida, um regime prolongado de esteroides de baixa dose terão níveis mínimos de reação da córnea.
|
24 meses
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Michael J Endl, MD, Fichte, Endl & Elmer Eyecare
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FEE17-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Mitomycin C
-
International Centre for Diarrhoeal Disease Research...University of California, DavisConcluídoCrianças Desnutridas
-
Nicholas M MohrWashington University School of Medicine; Hennepin County Medical Center, MinneapolisRetirado
-
University of MiamiRecrutamentoSíndrome do Coração Esquerdo HipoplásicoEstados Unidos
-
Massachusetts General HospitalNational Center for Complementary and Integrative Health (NCCIH)Ativo, não recrutandoAnsiedade | MTBI - Lesão Cerebral Traumática LeveEstados Unidos
-
Otto Bock Healthcare Products GmbHConcluídoAmputação de membro inferior acima do joelho (lesão)Áustria, Bélgica
-
Eli Lilly and CompanyConcluído
-
U.S. Army Medical Research and Development CommandPPD; Idorsia Pharmaceuticals Ltd.; Berry Consultants; Cambridge Cognition Ltd; Cit...RecrutamentoTranstorno de Estresse Pós-TraumáticoEstados Unidos
-
Direction Centrale du Service de Santé des ArméesRecrutamentoHábito alimentar | Exposição ao Frio | AquecerFrança
-
Assiut UniversityDesconhecidoLeucemia linfocítica crônica
-
Medical University of WarsawConcluído